Virpax Pharmaceuticals, Inc. VRPX
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -47.04% | -5.23% | 37.86% | 32.13% | 30.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.69% | 0.09% | 17.40% | -1.60% | -14.64% |
| Operating Income | 28.69% | -0.09% | -17.40% | 1.60% | 14.64% |
| Income Before Tax | 20.55% | 2.76% | -12.87% | 6.35% | 29.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.55% | 2.76% | -12.87% | 6.35% | 29.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.55% | 2.76% | -12.87% | 6.35% | 29.84% |
| EBIT | 28.69% | -0.09% | -17.40% | 1.60% | 14.64% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 59.19% | 24.13% | -3.65% | 6.35% | 29.85% |
| Normalized Basic EPS | 62.29% | 19.70% | -9.02% | 2.28% | 16.35% |
| EPS Diluted | 59.19% | 24.13% | -3.65% | 6.35% | 29.85% |
| Normalized Diluted EPS | 62.29% | 19.70% | -9.02% | 2.28% | 16.35% |
| Average Basic Shares Outstanding | 263.73% | 91.65% | 17.19% | -0.11% | -0.11% |
| Average Diluted Shares Outstanding | 263.73% | 91.65% | 17.19% | -0.11% | -0.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |